Tumor necrosis factor-alpha (TNF-α) inhibitors, such as infliximab (IFX) and adalimumab, are proinflammatory cytokines that are effective against moderate and severe Crohn’s disease and ulcerative colitis. Here, TNF is linked to ulcerative colitis.